Neumora Therapeutics, a Watertown, MA-based clinical-stage biotechnology company, raised $112M in Series B funding.
The round was led by Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, and Polaris Partners. Alaa Halawa, partner and head of U.S. Ventures at Mubadala Capital, joined Neumora’s board of directors.
The company intends to use the funds to support the advancement of a broad clinical and preclinical pipeline of novel precision medicine candidates for neuropsychiatric disorders and neurodegenerative diseases and the development of the its precision neuroscience platform.
Led by CEO Paul L. Berns, Neumora Therapeutics is a clinical-stage biotechnology company providing precision medicines for brain diseases through the integration of data science and neuroscience. Its data-driven precision neuroscience platform cuts through brain disease heterogeneity to match the right patient populations to targeted therapeutics. The company recently completed enrollment in a Phase 2a clinical trial for NMRA-140, a kappa opioid receptor antagonist in development for the treatment of major depressive disorder. It is also advancing NMRA-511, a clinical-stage vasopressin 1a receptor antagonist in development for neuropsychiatric disorders, and NMRA-266, an M4 muscarinic receptor positive allosteric modulator being advanced toward initiation of Phase 1 development for schizophrenia in 2023.
FinSMEs
11/10/2022